Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Unknown 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 48fludarabine phosphate 36Methotrexate 26Cytarabine 24fludarabine 23Whole-Body Irradiation 23Rituximab 19Cyclosporine 19Antilymphocyte Serum 18Peripheral Blood Stem Cell Transplantation 17Filgrastim 17Busulfan 17Mycophenolic Acid 16Tacrolimus 15Azacitidine 15Alemtuzumab 15Radiotherapy 13Melphalan 13Imatinib Mesylate 13Etoposide 13Vincristine 11Methylprednisolone 11Cord Blood Stem Cell Transplantation 11Dexamethasone 10venetoclax 8Granulocyte Colony-Stimulating Factor 8Clofarabine 8thymoglobulin 7sargramostim 7nilotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡